Analyst Casts Doubts On Merus' Lung Candidate Safety Profile
Earlier today, Merus N.V. (NASDAQ: MRUS) announced the publication of the abstract highlighting interim data from the ongoing phase 1/2 trial of the bispecific antibody MCLA-129 in advanced non-small cell lung cancer (NSCLC) and other solid tumors.
Needham says that the first clinical data readout from MCLA-129 suggests that the drug has a clinical profile comparable to Johnson & Johnson's (NYSE: JNJ) Rybrevant (amivantamab).
The analyst keeps the Buy rating and a price target of $45.
Also Read: Needham Says Merus' ASCO Update On Zeno 'Positive'
While available data are limited efficacy appears to be comparable, and MCLA-129 saw one ≥ Grade 3 infusion-related reaction, whereas the analyst had not seen any with amivantamab at the WCLC 2018 update.
13 patients were evaluable for response with preliminary signs of anti-tumor activity observed, including two partial responses (one confirmed) in EGFR mt NSCLC and four confirmed stable disease.
The analyst says that while expectations for MCLA-129 have come down, with the stock down ~20% over the past month, investors were looking for a competitive clinical profile.
Price Action: MRUS shares are up 1.71% at $19.66 on the last check Wednesday.
Latest Ratings for MRUS
Date | Firm | Action | From | To |
|---|---|---|---|---|
Feb 2022 | BMO Capital | Initiates Coverage On | Outperform | |
Feb 2022 | Needham | Initiates Coverage On | Buy | |
Nov 2021 | HC Wainwright & Co. | Maintains | Buy |
View More Analyst Ratings for MRUS
View the Latest Analyst Ratings
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
